Abstract：【Objective】To analyze the effects of Pivastatin combined with Trimetazidine on neuroendocrine factors and cardiac function in patients with chronic heart failure. 【Methods】One hundred and thirty-six patients with chronic heart failure admitted to our hospital were divided into observation group (trimetazidine + pitavastatin, n=70) and control group (trimetazidine, n=66) according to different medications. The cardiac function indexes [left ventricular end systolic diameter (LVESD), left ventricular end diastolic diameter (LVEDD) and left ventricular ejection fraction (LVEF)], 6-minute walking test, plasma levels of neuroendocrine factors [plasma atrial natriuretic peptide (ANP), plasma brain natriuretic peptide (BNP), plasma endothelin (ET)] were compared between the two groups before and after treatment. 【Results】After treatment, the LVEDD and LVESD of the two groups were lower than before treatment, and the LVEF was higher than before treatment, and the difference between the two groups was statistically significant (P<0.05). After treatment, the 6-minute walking distance of the observation group and the control group was greater than that before treatment, and the observation group was larger than that of the control group, the difference was statistically significant (P<0.05). After treatment, the levels of plasma ANP, BNP and ET in the two groups were lower than those before treatment, and those in the observation group were lower than those in the control group (P<0.05).【Conclusion】Pivastatin combined with trimetazidine can effectively inhibit the overactivation of neuroendocrine system and reverse ventricular remodeling in patients with chronic heart failure. It has a good effect and is worthy of clinical application.
谭德胜, 曹刚, 徐强, 梁心慧, 周凤, 沈颖, 林琳, 许宁. 匹伐他汀联合曲美他嗪对慢性心衰患者神经内分泌因子及心功能的影响[J]. 医学临床研究, 2019, 36(8): 1531-1532.
TAN De-sheng, CAO Gang, XU Qiang,et al. Effect of Pivastatin Combined with Trimetazidine on Neuroendocrine Factor and Cardiac Function in Patients with Chronic Heart Failure. JOURNAL OF CLINICAL RESEARCH, 2019, 36(8): 1531-1532.
2019, Vol. 36 
